atherosclerotic cardiovascular disease
Cardiovascular · 2017–2022
2decisions
2medicines
2carried consumer input
15individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| evolocumab Extension of existing PBS listings for atherosclerotic cardiovascular disease (ASCVD) with high risk factors (including familial hypercholesterolaemia) to… | Jul 2022 | Recommended with restriction | 2 individuals |
| alirocumab Heterozygous familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease in patients with inadequate control on statins and… | Nov 2017 | Not recommended | 13 individuals |
What the PBS pays
$63M in government benefit over 2024–25, across 176,912 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| evolocumab | $63.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.